www.renalandurologynews.com NOVEMBER/DECEMBER 2020
Renal & Urology News 3
News in Brief
Please visit us at www.renalandurologynews.com for the latest news updates from the fields of urology and nephrology
Short Takes Subcutaneous Fat Affects mCRPC Therapy Response
patients who underwent abdomino-
Greater subcutaneous fat is associated
patients younger than 10 years and
with improved response to chemother-
older than 90 years, as well as patients
apy combined with maximal androgen
undergoing kidney, ureter, and bladder
ablation among men with metastatic
scans for urolithiasis-associated symp-
castration-resistant prostate cancer
toms and those with already known
(mCRPC), according to data presented
urolithiasis. Incidental stones were
at the European Society for Medical
found in 20 patients: 11 male and 9
Oncology Virtual Congress 2020.
female. Of the 20 stones, 18 were in
In a study of 58 men with mCRPC,
pelvic CT scans. The study excluded
the kidneys and 2 were in the ureters.
Andrew E. Hahn, MD, of The University in Houston, and colleagues found
CKD Worsens Prognoses in Patients With VTE
that patients who had an objective re-
Patients with venous thromboembo-
sponse to chemotherapy plus maximal
lism (VTE) and concomitant moderate
androgen ablation had a significantly
to severe chronic kidney disease
higher subcutaneous adipose tissue
(CKD) have worse prognoses com-
index than those who had no response
pared with those who have VTE but no
(87.9 vs 62.7 cm2/m2).
or mild CKD, data suggest.
of Texas MD Anderson Cancer Center
In a cohort study of 8979 adult pa-
New Study Characterizes Incidental Urinary Stones
tients with VTE, patients with moderate
Computed tomography (CT) revealed
risk of all-cause mortality, major
incidental urinary stones in 2.8% of pa-
bleeding, and recurrent VTE within 12
tients in a Pakistani study, according to
months of VTE diagnosis compared
a report in Cureus (2020;12:e1037).
with patients with no or mild CKD, in ad-
Sajeel Saeed, MD, and colleagues
justed analyses, Shinya Goto MD, PhD,
to severe CKD had a 1.4-fold increased
at Rawalpindi Medical University in
of Tokai University School of Medicine
Rawalpindi, Pakistan, retrospectively
in Kanagawa, Japan, and colleagues
reviewed findings from 721 consecutive
reported in JAMA Network Open.
SBRT Outcomes Durable Stereotactic body radiation therapy (SBRT) for localized prostate cancer offers high rates of long-term oncologic control with mild toxicity, according to study results presented at the American Society for Radiation Oncology 2020 virtual annual meeting. Shown here are the 12-year rates of biochemical disease-free survival (bDFS) stratified by risk category.
12-YEAR BDFS
Low risk: 92%
Intermediate risk: 79.1%
High risk: 64% 0
20
40
60
80
100
Source: Katz AJ, Kang J. Efficacy and toxicity of stereotactic body radiation therapy for localized prostate cancer: A twelve year study. Presented at: ASTRO 2020 virtual annual meeting, October 25 to 28. Poster 4026.
Shortened Course of PTNS Effective in OAB, Data Show A
shortened 6-week protocol of percutaneous tibial nerve stimulation (PTNS) can effectively treat refractory nonneurogenic overactive bladder (OAB), according to data presented at the European Association of Urology 2020 virtual congress. Ahmed M. Lashin, MD, and colleagues of Mansoura University in Mansoura, Egypt, randomly assigned 50 patients to receive 6 weekly PTNS treatments or sham therapy. Fifty-two percent of the PTNS group reported significant, moderately improved symptom scores after week 7 and months 3 and 6, compared with no patients in the sham therapy group. According to voiding diaries at 6 weeks, PTNS patients had significant improvements in frequency, voided volume, and urge incontinence episodes compared with sham therapy. No serious device-related adverse events or malfunctions were reported. “The duration of treatment with PTNS can be halved compared to the conventional 12 weeks, which would make it more acceptable and cost effective for patients,” Dr Lashin’s team concluded in a study abstract.
Pulse Pressure Prior to HD May Predict Mortality Risk P
atients’ pulse pressure (PP) prior to hemodialysis (HD) sessions may predict mortality, investigators reported at the American Society of Nephrology’s Kidney Week 2020 Reimagined virtual conference. The finding may aid in HD patient risk stratification. Consistently high PP values are associated with arterial stiffness, whereas low PP values may be associated with congestive heart failure, the investigators explained. The association between pre-HD PP with mortality among HD patients is not well understood. Based on an analysis of data from 152,625 patients receiving HD at Fresenius Medical Care facilities, Hanjie Zhang, PhD, and colleagues at the Renal Research Institute in New York, found that the association of pre-HD PP with mortality is nonlinear: pre-HD PP less than 49.2 mm Hg and higher than 74.7 mm Hg were associated with higher mortality compared with a PP range of 49.2 to 74.7 mm Hg.
Race Disparity in Survival Absent in Metastatic PCa N
o racial differences exist in survival outcomes of men with metastatic prostate cancer (PCa), but the mortality risk among men with nonmetastatic PCa is higher for Blacks than Whites, according to study findings presented at the American Society for Radiation Oncology 2020 virtual annual meeting. The study, by Toms Vengaloor Thomas, MD, and colleagues at the University of Mississippi Medical Center in Jackson, was a retrospective review of data from 26,639 patients with bone metastases, 952 with metastases at locations other than bone, such as the liver, lung, and brain, and 579,202 without metastases. The investigators found no significant difference in survival between Black and White PCa patients with bone metastases or with metastases at other sites. Among men with nonmetastatic PCa, however, Blacks had a significant 17% increased risk of death compared with Whites.
